Loading the session
Loading the session
Loading instrument
$86.40
+7.12%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:28 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +32.5% (SPY −1.6%, XLV +13.5%). 3 months: +22.2% (SPY −0.4%, XLV +15.5%). 1 year: +15.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GEHC, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $85.81 was 24.5% above its 50-day average ($68.91) and 22.9% above its 200-day average ($69.83). It has closed above the 200-day for 10 sessions, since 22 Oct 2026. The 50-day average crossed below the 200-day on 7 Apr 2026, 147 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 4 Nov 2026 gain of 6.4% was 4.1× its average daily move of 1.6% over the past year, and its largest one-day gain since 28 Oct 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
Closed at $85.81 on 4 Nov 2026: 4.4% below the 52-week high of $89.77 (8 Jan 2026) and 46.1% above the low of $58.75 (29 Apr 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
19.4M shares were sold short at the 15 Oct 2026 settlement, 4.3% of the 452.1M shares outstanding; covering them would take 5.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
April 29, 2026
−13.16%April 4, 2025
−15.96%April 30, 2024
−14.28%